Vikram Verghese Sells 6,640 Shares of Heartflow (NASDAQ:HTFL) Stock

Posted by George Bondi on Sep 12th, 2026

Heartflow, Inc. (NASDAQ:HTFL – Get Free Report) CFO Vikram Verghese sold 6,640 shares of the stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $50.03, for a total transaction of $332,199.20. Following the sale, the chief financial officer directly owned 214,503 shares in the company, valued at $10,731,585.09. This trade represents a 3.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vikram Verghese also recently made the following trade(s):

On Thursday, September 3rd, Vikram Verghese sold 27,540 shares of Heartflow stock. The stock was sold at an average price of $49.69, for a total transaction of $1,368,462.60.
On Wednesday, September 2nd, Vikram Verghese sold 5,876 shares of Heartflow stock. The shares were sold at an average price of $50.60, for a total transaction of $297,325.60.

Heartflow Stock Up 9.7%

Shares of NASDAQ HTFL opened at $49.88 on Friday. The firm has a market cap of $4.34 billion and a P/E ratio of -27.26. Heartflow, Inc. has a twelve month low of $20.13 and a twelve month high of $51.78. The company has a 50 day moving average of $35.52 and a 200 day moving average of $30.78.

Heartflow (NASDAQ:HTFL – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15. The business had revenue of $64.08 million during the quarter. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.Heartflow’s revenue for the quarter was up 47.7% on a year-over-year basis. As a group, equities analysts expect that Heartflow, Inc. will post -0.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on HTFL. Canaccord Genuity Group upped their target price on shares of Heartflow from $37.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, August 14th. JPMorgan Chase & Co. boosted their price objective on shares of Heartflow from $35.00 to $45.00 and gave the company an “overweight” rating in a report on Friday, August 14th. Wells Fargo & Company increased their price objective on shares of Heartflow from $37.00 to $39.00 and gave the company an “overweight” rating in a research report on Friday, August 14th. Stifel Nicolaus raised their target price on shares of Heartflow from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, August 14th. Finally, Morgan Stanley boosted their target price on shares of Heartflow from $35.00 to $40.00 and gave the company an “equal weight” rating in a research note on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Heartflow currently has an average rating of “Moderate Buy” and an average target price of $44.88.

View Our Latest Analysis on HTFL

Institutional Investors Weigh In On Heartflow

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. bought a new position in shares of Heartflow in the 3rd quarter worth approximately $48,871,000. Legal & General Group Plc purchased a new stake in Heartflow during the third quarter valued at approximately $59,000. Franklin Resources Inc. bought a new position in Heartflow in the third quarter worth approximately $10,829,000. UBS Group AG purchased a new position in shares of Heartflow during the 3rd quarter worth $5,130,000. Finally, Sei Investments Co. bought a new stake in shares of Heartflow during the 3rd quarter valued at $303,000.

Heartflow Company Profile

(Get Free Report)

Heartflow, Inc is a medical technology company that develops artificial intelligence and imaging solutions for the diagnosis and management of coronary artery disease. Its platform analyzes data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries.

The company’s primary offering, Heartflow Analysis, is designed to provide noninvasive estimates of fractional flow reserve derived from computed tomography (FFR^CT).